peoplepill id: nicholas-j-vogelzang
NJV
United States of America
2 views today
2 views this week
Nicholas J. Vogelzang
American oncologist

Nicholas J. Vogelzang

The basics

Quick Facts

Intro
American oncologist
Places
United States of America
is
Scientist Oncologist
Work field
Healthcare Science
Gender
Male
Birth
13 December 1949 People who share this birthday
Place of birth
Holland
Age
75 years
The details (from wikipedia)

Biography

Nicholas J. Vogelzang is a medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN). He serves as Medical Director of the Research Executive Committee and Associate Chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research. His research interests include clinical trials for genitourinary malignancies and mesothelioma.

Career

Vogelzang joined Comprehensive Cancer Centers of Nevada in 2009 as a medical oncologist and serves as Medical Director of the Research Executive Committee and Associate Chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research. Since 2004, he has been Head of the Genitourinary Oncology and Clinical Professor of Medicine for the University of Nevada School of Medicine in Las Vegas and Reno, Nevada.

He served as Director, Executive Vice President for Academic Affairs and Professor at Nevada Cancer Institute (NVCI) from 2004 to 2009.

During his tenure at the University of Chicago, he served as Professor of Medicine and Surgery (Urology) (1993 to 2003), Director for the University of Chicago Cancer Research Center (1999–2003), and was named the first Fred C. Buffett Professor in Medicine and Chair in Genitourinary Oncology (1999–2003).

Vogelzang received his M.D. from the University of Illinois at Chicago in 1974. He completed his internship, residency and chief residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center in Chicago, followed by his fellowship in medical oncology at the University of Minnesota in Minneapolis. Vogelzang became the first editor of the Textbook of Genitourinary Oncology and remains the lead editor today.

Research

In 2002, Vogelzang directed the largest Phase II trial for mesothelioma using pemetrexed (brand name Alimta, by Eli Lilly). Pemetrexed is an antifolate, a class of drugs that targets the folic acid metabolic pathway. The results of the trial showed tumors shrank in 41 percent of patients on pemetrexed in combination with a more commonly used chemotherapy agent called cisplatin. Only 17 percent of patients receiving cisplatin alone experienced tumor shrinkage. Additionally, those on the pemetrexed combination lived nearly three months longer than those on cisplatin alone.

Active research support

Vogelzang is actively involved in many research studies to test new therapies and treatments including:

  • A double-blind, randomised, multiplied dose, Phase III, multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases. The study began in October 2010 and is supported by Algeta USA.
  • A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy. The study began in March 2010 and is supported by Cougar Biotechnology.
  • A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer. The study began in April 2009 and is supported by Cougar Biotechnology.
  • A Registry of Sipuleucel-T Therapy in men with advanced prostate Cancer. The study began in June 2010 and is supported by Dendreon.
  • A Phase 1/2., Open label, dose escalation, selected dose comparison trail of TOK-001 for the Treatment of Chemotherapy naïve castration resistant Prostate Cancer. The study began in September 2009 and is supported by Tokai.

Professional memberships

Vogelzang served on committees for the American Society of Clinical Oncology (ASCO), as well as its board of directors from 1993 to 1996, and is a former president of the Illinois Division of the American Cancer Society. Vogelzang was the principal investigator at the University of Chicago for Cancer and Leukemia Group B (CALGB) from 1988 to 1999, and chair of the CALGB Prostate Committee from 1993 to 1999.

He is a founding board member of the Mesothelioma Applied Research Foundation (MARF) and a member the American Association for Cancer Research, the American Urological Association, the Society of Urologic Oncology and the European Society for Medical Oncology. Vogelzang is the 2012 Chair for the American Society of Clinical Oncology's (ASCO) Cancer Communications Committee, the current Vice Chair of the GU Committee and a member of the GU Translational Medicine Intergroup Committee for Southwest Oncology Group. For more than ten years, Vogelzang has served on the Medical and Scientific Advisory Boards for Us TOO, a prostate cancer education and support network for persons affected by prostate cancer.

Vogelzang is also a current or past member of several medical societies including:

  • American Association of Cancer Research (AACR)
  • American College of Physicians (ACP)
  • American Foundation for Urologic Disease
  • American Society of Clinical Oncology (ASCO)
  • American Urological Association (AUA)
  • Chicago Urological Society (Honorary)
  • Clark County Medical Society
  • European Society for Medical Oncology (ESMO)
  • International Association for the Study of Lung Cancer (IASLC)
  • Kidney Cancer Association (KCA)
  • Mesothelioma Applied Research Foundation (MARF)
  • Nevada Oncology Society (NOS)
  • Society of Urologic Oncology (SUO)
  • Southwest Oncology Group

Corporate relationships

Vogelzang is a corporate consultant for the following companies: Aveo Pharmaceuticals Inc., Celgene Corporation, Dendreon, Exelixis Inc., Novartis AG, OncoGeneX/Teva Pharmaceutical Industries Ltd., Veridex, and Viamet.

He is also a member of the speakers' bureaus for Caris Life Sciences, Dendreon, Eli Lilly and Company, Inc., Novartis AG, and Sanofi-Aventis U.S.

Published works

  • Roth BJ, Krilov L, Adams S, Aghajanian CA, Bach P, Braiteh F, Brose MS, Ellis LM, Erba H, George DJ, Gilbert MR, Jacobson JO, Larsen EC, Lichtman SM, Partridge AH, Patel JD, Quinn DI, Robinson LL, von Roenn JH, Samlowski W, Schwartz GK, Vogelzang NJ: Clinical cancer advances 2012: Annual report on progress against cancer from the American Society of Clinical Oncoloy J Clin Oncol 2013 January 1
  • Sonpavde G, Pond, GR, Fougeray R, Choueiri Tk, Au AQ, Vaughn DJ, Niegisch G, Albers P, James ND, Wong YN, Ko YJ, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Vogelzang NJ, Beer TM, Stadler WM, O'Donnell PH, Sternberg CN, Rosenberg JE, Bellmunt J: Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advance urothelial carcinoma Eur Urol. 2012 Nov 26
  • Smith DG, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn UN, Vogelzang NJ, Small AL, Harzstark,MS, Gordon UN, Vaishampayan NB, Hass AI, Alexander I, Spira PN, Primo Nl JR, Lin CC, Srivivas S, Sella A, Schoffski P, Scheffold C, Weitzman AL, Hussain M: Cabozantinib in patients with advanced prostate cancer:results of a phase II randomized discontinuation trial J Clin Oncol. 2012 Nov 19
  • Yuh BE, Ruel N, Wilson TG, Vogelzang N, Pal SK (May 2013). "Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer.". J Urol. 189 (5): 1682–6. doi:10.1016/j.juro.2012.10.120. PMID 23123547. 
  • Dreicer R, Garcia JA, Rini B, Vogelzang N, Srinivas S, Somer B, Peipei S, Kania M, Raghavan D: A randomized, double-blind, placebo-controlled, phase 2 study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castrate-resistant metastatic prostate cancer submitted to Investigation New Drug (IND)
  • Jonasch E, Signorovitch JE, Lin PL, Liu Z, Culver K, Pal SK, Scott JA, Vogelzang NJ: Treatment patterns in metastatic renal cell carcinoma: A retrospective chart review in US community oncology practices Submitted Journal of Oncology Practice (JOP)
  • Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB JR, Sternberg CN, Li JH, Kheoh T, Haqq CM, De Bono JS; for the COU-AA-301 Investigatiors; Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer; final overall survival analysis of the COU-AA-301 radnomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012 Oct 13; Epub 2012 Sept 18
  • Vogelzang NJ, Bhor M, Liu Z, Dhanda R, Huston TE,: Everolimus vs. Temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology network. Clin Genitourin Cancer. 2012 Oct 11
  • Hong DS, Gordon MS, Samlowski WE, Kurzrock R, Tannir N, Friedland D, Mendelson DS, Vogelzang NJ, Rasmussen E, Wu BM, Bass B, Zhong ZD, Friberg G, Appleman LJ: A phase 1, open –label study of trebananib (AMG 386) combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma Trebanib (AMG 386)
  • Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, Demarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA 3rd, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA; Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase 1 dose-escalation trial Lancet Oncol. 2012 Jul 13. (epub ahead of print)
  • Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Janne PA, Quinn Dl, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato III SG, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE; Multicenter, Double-Blind Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma. 2012 June 4. (e-pub ahead of print)
  • Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP Jr, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM. , J Clin Oncol. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. 2011 May 20;29(15):2040-5. doi:10.1200/JCO.2010.32.2776 PMID 21502546
  • Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, Bellmunt J., "A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011 Mar;12(3):211-4.
  • Smith DC, Tangen CM, Hussain MHA, Van Veldhuizen, Jr PJ, Hartner GW, Stuart RK, Mills GM, Vogelzang NJ, Thompson IM. Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Combination with Hormone Therapy in Patients with High-Risk Metastatic Adenocarcinoma of the Prostate. Southwest Oncology Group (SWOG) S0032 Urology 2011 Feb 18
  • Shapiro GI, Tibes R, Gordon MS, Wong BY, Eder JP, Borad MJ, Mendelson DS, Vogelzang NJ, Bastos BR, Weiss GJ, Fernandez C, Sutherland W, Sato H, Pierceall WE, Weaver D, Slough S, Wasserman E, Kufe DW, Von Hoff DD, Kawabe T, Sharma S: Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid tumors. Clinical Cancer Res. 2011 January 10. (e-pub ahead of print)
  • Galsky MD, Hahn NM, Rosenberg J, Sonpavde S, Hutson T, Oh W, Dreicer R, Vogelzang NJ, Sternberg C, Bajorin D, Bellmunt D. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. Journal of Clinical Oncology 2011 (IN PRESS)
  • Agarwal N, Vogelzang NJ., BJU Int., Secondary hormonal manipulations in the treatment of castration refractory prostate cancer. 2011 Jul;108(2):227-8. doi: 10.1111/j.1464-410X.2010.09970.x. Epub 2010 Nov 24.

In the media

Awards and Honors

Vogelzang has been recognized for his work by many of the leading medical groups and research organizations in the United States. Some of his notable honors include:

  • Member of the Board of Advisors, Johns Hopkins Greenberg Bladder Cancer Institute - 2014
  • Named one of the "Top Doctors - Medical Oncology" in Vegas Seven - May 2014
  • Laureate Award and medallion of The ACP Nevada Chapter - 2013
  • Distinguished Physician of the year, The Nevada State Medical Association, 2013
  • Named one of the "Best Physicians in Southern Nevada as chosen by their peers" in Desert Companion - August 2012
  • Received Everyday Hero Award from American Red Cross Las Vegas - October 2011
  • Named Healthcare Headliner by VEGAS Inc. magazine - October 2011
  • Awarded Gold Certificate of Excellence by National Cancer Institute - October 2011
  • Named Top Doctor by U.S. News & World Report - 2011
  • Honored with a service award for his more than 10 years on the board of the Mesothelioma Applied Research Foundation - June 2011
  • "Best Doctors in Las Vegas: Research" by Las Vegas Life - 2011
  • Schonfeld Memorial Lecture, Kidney Cancer Association 20th Anniversary meeting - Chicago, October 2010
  • Keynote Speaker, Japanese Society for Renal Cancer, 40th Anniversary - Tokyo, June 2010

The contents of this page are sourced from Wikipedia article. The contents are available under the CC BY-SA 4.0 license.
Lists
Nicholas J. Vogelzang is in following lists

By field of work

Notable American people in healthcare and medicine

Gender:Male, Born in:Years 1930 to 1969

Notable American scientists

Gender:Male, Born in:Years 1930 to 1969

By work and/or country

Notable American Scientists

Gender:Male, Born in:Years 1930 to 1969

Notable American Oncologists

Gender:Male, Born in:Years 1930 to 1969
comments so far.
Comments
From our partners
Sponsored
Nicholas J. Vogelzang
arrow-left arrow-right instagram whatsapp myspace quora soundcloud spotify tumblr vk website youtube pandora tunein iheart itunes